REG-EMA — PRAC Semaglutide NAION "Very Rare" Classification

[DRAFT — authored 2026-04-18. Regulatory reference.]

Source

European Medicines Agency (EMA), Pharmacovigilance Risk Assessment Committee (PRAC), June 2-5, 2025 meeting. Referral outcome on semaglutide medicines (Ozempic, Rybelsus, Wegovy) re: non-arteritic anterior ischemic optic neuropathy (NAION).

External URLs:

Key Conclusions

NAION classification: PRAC concluded that NAION is a "very rare" side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy). "Very rare" per EU definition: may affect up to 1 in 10,000 patients.
Risk estimate: Based on review of multiple large epidemiological studies, exposure to semaglutide in adults with type 2 diabetes is associated with an approximately two-fold increase in NAION risk compared with people not taking the medicine. This corresponds to approximately one additional case of NAION per 10,000 person-years of treatment.
Product Information update: PRAC recommended that product information for semaglutide medicines be updated to include NAION as a side effect with a frequency of 'very rare'. CHMP adoption and national-level label updates followed.

Clinical Guidance Issued

Patients experiencing sudden loss of vision or rapidly worsening eyesight during semaglutide treatment should contact their doctor without delay.
Treatment with semaglutide should be stopped if NAION occurs.

Scope of Evidence Reviewed

Hathaway 2024 (single-center cohort, PMID-38958939)
Danish/Norwegian cohort (n=424,152, PMID-39696569 – Danish Norwegian NAION Cohort)
Lakhani 2025 (180-country pharmacovigilance, PMID-40383360 – Lakhani 180 Countries GLP-1 Ocular Events)
Other regional pharmacovigilance datasets

Regulatory Divergence with FDA

As of April 2026, the US Food and Drug Administration (FDA) has NOT updated US labels for semaglutide products to include NAION. This EMA-FDA divergence is a practical consideration for clinicians in informed consent — EMA has formally recognized NAION as a semaglutide-associated adverse event; FDA has not yet done so.

Linked Peptides

Semaglutide

Related References

PMID-38958939 – Hathaway NAION Cohort (foundational single-center cohort)
PMID-39696569 – Danish Norwegian NAION Cohort (population-scale confirmation)
PMID-40383360 – Lakhani 180 Countries GLP-1 Ocular Events (pharmacovigilance with tirzepatide class-differentiation)

Orchestrator Notes

Landmark EMA regulatory action; first class-member receiving NAION-specific label update for the GLP-1 family.
Vilsbøll NAION incidence analysis presented at EASD25 supports the risk estimate.
FDA label update status should be checked at time of M5 lesson review; if FDA has updated, remove the "EMA-FDA divergence" framing.

REG-EMA-PRAC-Semaglutide-NAION-2025 – EMA NAION Very Rare